Abcuro
Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases
$66MSeries D
Role not disclosedLoading investors…
Loading investors…
Activity from announced rounds
Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases
Develops lead-212 targeted alpha therapies to treat cancer
Develops minimally invasive eShunt System to treat communicating hydrocephalus and other neurological diseases
Develops treatments for patients suffering from thromboembolic disease